We have used combinatorial chemistry with amino acid mixtures (X) at positions 6 to 23 in vasoactive intestinal peptide (VIP) to optimize binding affinity and selectivity to the rat VPAC 1 receptor. The most efficient amino acid replacement was a substitution of alanine at position 18 to diphenylalanine (Dip), increasing the displacement efficiency of 125 I-VIP by 370-fold. The [Dip 18 ]VIP(6 -23) was subsequently used to find a second replacement, employing the same approach. Tyrosine at position 9 was selected and the resulting [Tyr 9 ,Dip 18 ]VIP(6 -23) analog has a K i value of 90 nM. This analog was unable to stimulate cAMP production at 10 Ϫ6
Vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) are neuropeptides with widespread distribution in both the central and the peripheral nervous systems. Besides being a central neurotransmitter, VIP is involved in the nervous control of vascular and nonvascular smooth-muscle activity and endocrine and exocrine secretion (Fahrenkrug, 1993) . In addition to a neurotransmitter function, PACAP has been shown to be a neurotrophic factor that plays a role during the development of the brain (Arimura, 1998) . These peptides act through three distinct receptors: the PAC 1 , VPAC 1 , and VPAC 2 receptors. The PAC 1 receptor possesses a high-affinity binding site for PACAP, whereas the VPAC 1 and VPAC 2 receptors show high-affinity binding for both VIP and PACAP. These receptors belong to the secretin receptor family (Tams et al. 1998 ) that constitutes a subfamily of G protein-coupled receptors, each having seven transmembrane helices.
To investigate the physiological roles of the three different receptors, selective agonists and antagonists are required. All VIP or PACAP antagonists have modifications in the N-terminal part of the peptide, suggesting that the N-terminal part of VIP is responsible for the activation of the receptor. The N-terminal truncated form of PACAP, PACAP 6 -38, is an antagonist for the VPAC 2 and PAC 1 receptors (Robberecht et al., 1992; Dickinson et al., 1997 ]VIP(3-7)/growth hormone-releasing factor (GRF)(8 -27) has been described as the most potent and selective VPAC 1 antagonist (Gourlet et al., 1997a) with a K i value of 15 nM for the rat receptor, and [Lys 15 ,Arg 16 ,Leu 22 ]VIP(1-7)/GRF(8 -27) is described as a selective agonist IC 50 ϭ 1 nM (Gourlet et al., 1997b) . These analogs, however, consist mainly of the homologous peptide GRF, and binding to other homologous receptors for peptides in the glucagon/VIP/secretin peptide family could affect the interpretations of physiological studies using these two analogs. Likewise, [Arg 16 ] chicken secretin is reported as a selective VPAC 1 receptor agonist (Gourlet et al., 1996b) . The IC 50 values are 1 nM, 10,000 nM, and 3,000 nM for the VPAC 1 , VPAC 2 , and PAC 1 receptors, respectively, but [Arg 16 ] chicken secretin is also a potent agonist for the secretin receptor. As an alternative to the chimeric approach of homologous peptides, we have used a combinatorial approach with VIP as template. Thus, selectivity toward other homologous receptors with low affinity to VIP is initially preserved. In our laboratory, we have predominantly used rat as the model animal for studying the physiological features of VIP and PACAP. Consequently, rat VPAC 1 receptor is used as target for the generation of a selective VIP antagonist and agonist. Bogan and Thorn (1998) examined 2325 alanine mutants at protein interfaces for which the change in free energy of binding has been measured. They concluded that the free energy of binding is not evenly distributed across protein interfaces; instead, there are hot spots of binding energy made up of a small subset of residues in the interface. O'Donnell et al. (1991) made an alanine scan of VIP and found several side chains important for binding and biological responses. These side chains are probably situated at the ligand-receptor interface and minor chemical changes of these residues could result in an optimized binding. However, we have used a different approach. We assumed that it was most advantageous to optimize poor interactions in the VIP-VPAC 1 receptor interface and convert these to hot spots instead of trying to optimize a hot spot that already could be near the limited maximal binding energy. Thus, in our combinatorial approach, we have initially used amino acid mixtures with very different chemical properties at positions not important for binding, with the hope that a few of these positions are at the ligand-receptor interface and therefore a target for optimization of the ligand binding and receptor specificity.
Materials and Methods
Peptide Synthesis. Solid-phase peptide synthesis was performed using the 9-fluorenylmethyloxycarbonyl strategy as described in Ploug et al. (1998) . TentaGel S RAM (S ϭ 0.25 mmol/g; RAPP Polymere, Tü bingen, Germany) was used as resin and the synthesis was carried out either in single vessels or in a multiple-column peptide synthesizer (Holm and Meldal, 1989; Meldal et al., 1993) . Particular to these syntheses was the use of extended reaction times or double couplings for assembly of the Lys-Gln-Met-Ala-Val sequence of the peptides. Coupling of amino acid mixtures was generally carried out as described by Pinilla et al. (1992) using 1.1 Eq of amino acids in total and 1.1 Eq coupling reagent for a minimum of 2 h followed by a double coupling of 30 min or longer. Amino acid mixtures of similar chemical structure or properties (motive mixtures) were preferred to ensure near equimolar incorporation of the individual amino acids. Complete removal of the arginine side chain protecting group (2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl or 2,2,5,7,8-pentamethylchroman-6-sulfonyl) usually required a longer trifluoroacetic acid treatment than normally employed. All peptides are amidated in the C terminal and VIP truncated peptides are N-acetylated. The peptide identity was verified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry obtained using a Fisons TofSpec E instrument. The purity of the peptides was assessed by HPLC performed on a Waters 600 E instrument equipped with a Waters 996 Photodiode Array Detector using Waters Radial Pak or Waters Symmetry RP C-18 column. Peptides devoid of X positions were purified by preparative HPLC with crude product purities lower than ϳ80%. Verification of amino acid composition and concentration determinations of the final aqueous peptide solutions was done by amino acid analysis using Waters PICOTAG system. VIP and PACAP 1-27 were purchased from Peninsula Laboratories, Inc., (Belmont, CA). Iodination and RP C-18 HPLC purification of 125 I-VIP and 125 I-PACAP 1-27 were conducted as described for VIP by Martin et al. (1986) .
Cell Lines Used for Receptor Characterization. The coding region of rat VPAC2 or rat PAC1 receptors [obtained from Dr. Anthony Harmar (Lutz et al., 1993) and Dr. Stephen Wank (Wank and Pisegna, 1993) , respectively] was subcloned into pcDNA3 from Invitrogen (Leek, The Netherlands). Human embryonic kidney (HEK) 293 cells were transfected transiently by the calcium phosphate precipitation technique (Gorman, 1988) . Cells were plated into a 200-mm diameter culture dish (4 ϫ 10 6 cells/dish). Ten micrograms of receptor cDNA was used for transfection and the cells were harvested 72 h later or seeded to 24-well culture dishes 48 h later. Transfected cells were grown in Eagle's minimum essential medium (Biological Industries, Kibbutz Beit Haemek, Israel) supplemented with 10% fetal calf serum (Biological Industries) and 0.1% gentamicin. Stable transfection of the rat VPAC 1 receptor in CHO cells was as described by Wulff et al. (1997) .
General DNA manipulations were performed as described by Sambrook et al. (1989) . DNA fragments required for subcloning experiments were gel-purified using Geneclean kit (BIO 101, Inc., KEBO lab, Albertslund, Denmark). Restriction enzymes were purchased from Amersham (Birkerød, Denmark).
Membrane Preparations from CHO and HEK293 Cells. Confluent monolayers of transfected or wild-type CHO and HEK293 cells were washed with 0.1 M PBS and detached from their plastic support using a cell scraper. The cells, solubilized in 20 ml of 25 mM HEPES, 2.5 mM CaCl 2 , 1.0 mM MgCl 2 , 50 mg/l bacitracin, pH 7.4 per plate, were disrupted using a Polytron (Ultra-Turrax T25, Janke & Kunkel GMBH, Bie & Berntsen, Rødovre, Denmark) for 30 sec. The homogenate was spun for 20 min at 30,000g at 4°C. The resulting pellet was resuspended in 15 ml of 25 mM HEPES, 2.5 mM CaCl 2 , 1.0 mM MgCl 2 , 50 mg/l bacitracin, pH 7.4 per plate. The preparation was aliquoted and stored at Ϫ80°C.
Binding Assay. Ten micrograms of membrane protein was incubated at room temperature, for 90 min, in a total volume of 0.15 ml containing 24 mM HEPES, pH 7.4, 2.5 mM CaCl 2 , 3.0 mM MgCl 2 , 100 mM NaCl, 0.5 g/l bacitracin, 15 pM 125 I-VIP or 125 I-PACAP 1-27, and increasing concentrations of unlabeled peptide. Nonspecific binding was determined in the presence of 1 M VIP. The separation of membrane bound and free radioactivities was achieved by centrifugation at 20,000g for 5 min. The apparent IC 50 value was estimated from a sigmoid dose-response equation
, where X is the concentration, Y is the response, and P is the slope factor. The affinity constant (K i ) of the nonlabeled ligand is then calculated using the formula of Cheng and Prusoff (1973) :
, where D is the concentration of the labeled ligand and K d its affinity constant. Iodination, HPLC purification, and binding curves of nonradioactive I-VIP have been made. The K d value for I-VIP was determined to be 0.42 Ϯ 0.05 nM and 1.1 Ϯ 0.3 nM for rVPAC 1 and rVPAC 2 receptors, respectively; finally, the K d value for I-PACAP binding to rPAC 1 was determined to be 2.9 Ϯ 0.8 nM.
Intracellular cAMP Assay. CHO or HEK293 cells were seeded at 2 ϫ 10 5 cells/well into 24-well culture dishes and incubated for 24 h at 37°C with Roswell Park Memorial Institute medium (Biological Industries), 10% fetal calf serum, and 0.2 M L-glutamine. To the CHO cells expressing the VPAC 1 receptor, an extra 0.8 mg/ml G418 (geneticin, Life Technologies, Gaithersburg, MD) was added. After two washes with Dulbecco's modified Eagle's medium (Biological Industries), 0.5% newborn calf serum (Biological Industries), and 0.2 M L-glutamine, the cells were incubated with 500 l of Dulbecco's modified Eagle's medium, 0.5% newborn calf serum, 0.2 M L-glutamine, 0.1 mM 3-isobutyl-1-methylxanthine (Boehringer Ingelheim Bioproducts Partnership, Ingleheim, Germany), 20 M H89 (protein kinase inhibitor; Calbiochem, San Diego, CA) for 10 min and for a further 20 min at room temperature with ligand in increasing concentrations (0-10 Ϫ6 M). cAMP was extracted by incubating the cells with 100 l of 20 mM HCl and neutralized by 2 l of 1 M sodium acetate. The amount of cAMP produced by the cells was quantified using a cAMP radioimmunoassay kit from Amersham (Paisley, UK). The apparent EC 50 was estimated from a sigmoid dose-response equation as detailed under Binding Assay. The antagonistic properties of the analogs have been determined using the Gaddum equation (Gaddum, 1957) 
Results
Selection of Template and X Positions. We were interested in a template having a reduced length, which 1) simplifies peptide synthesis and 2) increases the potential bioavailability of an antagonist. Initially, several truncated VIP analogs were tested for the ability to displace 125 I-VIP on the rat VPAC 1 receptor. The truncated VIP(6-23) was chosen because we expected that removal of the first five residues would convert the peptide to an antagonist (see under Discussion). The five residues at the C terminal are of less importance for VIP binding to the VPAC 1 receptor and they were therefore omitted to reduce the size of the template. Furthermore, this template has a reasonable ratio of peptide size versus binding affinity (K i ϭ 110 Ϯ 30 M) to the rat VPAC 1 receptor.
The residues important for VIP binding in the 6-23 part of VIP are residues F6, T7, Y10, R14, Y22, and L23 (O'Donnell et al., 1991) . These residues were preserved in our 6-23 VIP template together with R12, K15, K20, and K21, which were preserved to ensure high solubility of the peptide. The VIP-VPAC 1 receptor interface is not known, but the remaining residues are presumably either 1) poorly fitted residues at the interface or 2) exposed to the solvent. Thus, the positions selected for scanning with a mixture of amino acids (X) were D8, N9, T11, L13, Q16, M17, A18, and V19.
Selection of the First Amino Acid Replacement. A broad amino acid mixture containing various side-chain sizes and hydrophilicity was used initially and the results of the displacement of 125 I-VIP in a competitive binding assay are shown in Fig. 1 , top. The X replacement at positions 9, 16, and 18 had the most pronounced effect, and four different motive amino acid mixtures, Xa, Xb, Xc, and Xd, with fewer, similar amino acids were used in the second scan at these three positions (Fig. 1, middle) . Amino acid mixture Xc was most efficient at all three positions, especially at position 18, where the relative 125 I-VIP binding was decreased to 30%. Each of the four different amino acids in the Xc mixture [W, ␤-benzothienyl-Lalanine, ␤-2-naphthyl-L-alanine (Nal-2), and ␤,␤-diphenyl-Lalanine (Dip)] was incorporated in positions N9, Q16, and A18 (Fig. 1, bottom ]VIP(6-23) was used as second template and a new scan with amino acid mixtures was done at positions 9 and 16 (Fig. 2) . The following motive amino acid mixtures were tested: mixture with small amino acids (Xe), polar amino acids (Xf), flexible amino acids (Xg), and hydrophobic amino acids (Xh). The substitution with hydrophobic amino acids at position 9 had a pronounced effect on the 125 I-VIP displacement efficiency, but none of the selected amino acid mixtures substituted at position 16 were productive (Fig. 2, top) . Several hydrophobic amino acids were substituted at position 9 (Fig. 2, bottom ) and the substitution with Tyr, Cha, S(Bzl), and Y(Bzl) were most efficient. The marked difference in displacement efficiency between N9Y and N9F indicates that the hydroxyl group of tyrosine is important for the binding efficiency. We expect that hydro- Properties of the Modified VIP(6-23) Analog and the C-and N-Terminal Extended Forms. Fig. 3 shows the binding curves of VIP(6-23) and VIP (6-23) ]VIP(1-28) is 5-fold more potent in stimulating cAMP production (EC 50 ϭ 0.23 Ϯ 0.01 nM) compared with VIP (EC 50 ϭ 1.12 Ϯ 0.06 nM) as seen in Fig. 4 . The cAMP response data using HEK293 cells transfected with rat VPAC 2 or rat PAC 1 receptor cDNA are shown in Fig. 5 Gourlet et al. (1996b Gourlet et al. ( , 1998 (Pandol et al., 1986; Gourlet et al., 1997a) , were also tested at the rat VPAC 1 receptor. As shown in Table 1 (Fig. 4) . The neurotensin/VIP chimera (Gozes et al., 1989) 
Discussion
We have chosen to use a combinatorial approach with a truncated VIP, 6 -23, as a template to optimize the VIP-VPAC 1 receptor binding to create a high-affinity, selective antagonist. The use of a truncated VIP as a template has the advantage, compared with other templates, of having initial binding ability and selectivity toward the VPAC receptors. Truncation of the first five residues was expected to convert the template to an antagonist (PACAP 6 -38 is an antagonist for the VPAC 2 and PAC 1 receptors), whereas the final five residues at the C terminal were less important for VIP binding to the VPAC 1 receptor and was therefore omitted to reduce the size of the template. All charged residues were preserved to ensure high solubility of the template but also because charged interactions are strong and able to direct the molecule at long distances; the energy of charged interactions is proportional to a factor of 1/radius (r). The energy of other noncovalent interactions are weaker and typically proportional to a factor of 1/r 6 (Fersht, 1985) . Thus, charged residues are important for the first events in the binding process and for the general solubility of a molecule in a biological environment (e.g., the degree of adsorption to other proteins and surfaces as the lipid membrane). The structure of the VIP-VPAC 1 receptor interface is not known, but amino acids that affect ligand binding by an alanine substitution (O'Donnell et al., 1991) are candidates to participate in the interaction at the binding interface. A crucial point in our 
